Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Biocryst Pharmaceuticals Inc

BCRX Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2016โ€“FY2025

Last close ยท Oct 23, 2026

$7.65

1.7%
Compare
Revenue Total sales reported in the income statement.
$875M
94.1% vs prior year
Operating margin Operating income as a share of revenue.
39.0%
39.5ย pts
Net income Profit after all expenses, interest and tax.
$264M
Free cash flow Cash from operations minus capital spending.
$345M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$2.0B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$1.49 EPS (TTM)

What Biocryst Pharmaceuticals Inc does

No business description yet.

Legal name
BIOCRYST PHARMACEUTICALS INC
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Feb 26, 2026
Accession ยท CIK
0001628280-26-012240
0000882796

Revenue and margins

Biocryst Pharmaceuticals Inc had $875M of revenue in fiscal 2025, up 94.1% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $345M in fiscal 2025, 39.4% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Biocryst Pharmaceuticals Inc returned โ€” to shareholders in fiscal 2025. The diluted share count rose 5.8%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Biocryst Pharmaceuticals Inc can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $508M$424M$389M$321M$275M
Debt incl. finance leases $298M$234M$308M$319M$2.8M
Net debt / EBITDA โ€”โ€”โ€”โ€”โˆ’0.8x
Interest coverage โˆ’3.0xโˆ’1.5xโˆ’1.0xโˆ’0.0x4.3x
Current ratio 5.5x4.9x3.3x2.6x2.1x
Quick ratio 5.3x4.6x3.1x2.6x2.0x
Total assets $588M$550M$517M$490M$514M
Total liabilities $695M$845M$972M$966M$633M
Shareholders' equity โˆ’$107Mโˆ’$295Mโˆ’$456Mโˆ’$476Mโˆ’$119M
Net debt (โˆ’ = net cash) โˆ’$209Mโˆ’$190Mโˆ’$81.3Mโˆ’$2.0Mโˆ’$272M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ“
Cash from operations is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ“
Return on assets rose โ€” โœ“ โœ• โœ“ โœ“ โœ“ โœ• โœ“ โœ“ โœ“
Cash from operations exceeds net income โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โœ“ โœ• โœ• โœ• โœ• โœ“ โœ• โœ• โœ“
Current ratio rose โ€” โœ“ โœ• โœ“ โœ“ โœ“ โœ• โœ• โœ• โœ•
Share count didn't rise โ€” โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โœ“ โ€” โ€” โœ• โœ“ โœ“ โœ“ โœ• โœ“
Revenue rose relative to assets โ€” โœ• โœ• โœ“ โœ• โœ“ โœ“ โœ“ โœ“ โœ“
F-score โ€” / 35 / 91 / 84 / 83 / 95 / 94 / 94 / 93 / 97 / 9
Accruals ratio โˆ’1.9%โˆ’18.4%โˆ’5.3%โˆ’12.0%โˆ’18.7%โˆ’9.1%โˆ’15.0%โˆ’24.6%โˆ’7.3%โˆ’16.6%
Altman Z'' โˆ’23.23โˆ’10.93โˆ’18.03โˆ’16.46โˆ’9.26โˆ’3.73โˆ’5.90โˆ’8.05โˆ’8.82โˆ’2.63

10 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $26.4M $25.2M $20.7M $48.8M $17.8M $157M $271M $331M $451M $875M
Gross profit $24.1M $24.0M โ€” $45.1M $16.3M $150M $264M $327M $438M $856M
Research and development $61.0M $67.0M $84.9M $107M $123M $209M $253M $217M $175M $166M
Operating income โˆ’$48.6M โˆ’$57.4M โˆ’$94.2M โˆ’$99.5M โˆ’$175M โˆ’$178M โˆ’$148M โˆ’$104M โˆ’$2.5M $341M
Interest expense $6.5M $8.6M $9.2M $11.9M $14.5M $59.3M $99.1M $108M $98.5M $78.9M
Pretax income โ€” โ€” โ€” โˆ’$109M โˆ’$183M โˆ’$182M โˆ’$244M โˆ’$226M โˆ’$87.0M $267M
Income tax $0.0M $0.0M $0.0M $0.0M $0.0M $2.3M $2.7M $0.3M $1.9M $3.5M
Net income โˆ’$55.1M โˆ’$65.8M โˆ’$101M โˆ’$109M โˆ’$183M โˆ’$184M โˆ’$247M โˆ’$227M โˆ’$88.9M $264M
Diluted EPS โˆ’$0.75 โˆ’$0.78 โˆ’$0.98 โˆ’$940.00 โˆ’$1.09 โˆ’$1.03 โˆ’$1.33 โˆ’$1.18 โˆ’$0.43 $1.21
Diluted shares 0.07B 0.08B 0.10B 0.12B 0.17B 0.18B 0.19B 0.19B 0.21B 0.22B
Cash flow
Cash from operations โˆ’$53.4M โˆ’$41.1M โˆ’$92.6M โˆ’$89.6M โˆ’$135M โˆ’$142M โˆ’$162M โˆ’$95.1M โˆ’$52.0M $347M
Capital expenditure $5.3M $0.3M $0.4M $0.3M $0.5M $2.4M $1.4M $2.2M $1.1M $2.5M
Free cash flow โˆ’$58.7M โˆ’$41.5M โˆ’$92.9M โˆ’$89.9M โˆ’$136M โˆ’$145M โˆ’$163M โˆ’$97.3M โˆ’$53.1M $345M
Depreciation and amortization $0.5M $0.7M $0.8M $0.7M $0.7M $0.8M $1.4M $1.7M $1.2M $1.4M
Stock-based compensation $8.5M $12.6M $9.4M $17.7M $14.8M $34.6M $44.7M $55.6M $65.4M $85.1M
Balance sheet
Cash and short-term investments $54.7M $114M $104M $136M $300M $508M $424M $389M $321M $275M
Total debt $23.0M $23.0M $30.0M $50.0M $123M $298M $232M $303M $315M $0.0M
Finance lease liabilities โ€” โ€” โ€” โ€” โ€” โ€” $2.6M $4.4M $4.0M $2.8M
Current assets $67.0M $125M $114M $164M $324M $566M $517M $496M $422M $404M
Current liabilities $54.4M $74.8M $69.5M $92.3M $106M $104M $106M $150M $160M $196M
Inventory $0.5M โ€” $1.6M $0.0M $7.0M $15.8M $27.5M $28.7M $8.1M $5.4M
Property and equipment, net $9.9M $9.5M $9.1M $7.3M $7.1M $8.7M $8.6M $7.9M $7.8M $8.8M
Total assets $89.8M $178M $147M $175M $335M $588M $550M $517M $490M $514M
Total liabilities $88.3M $94.5M $97.6M $137M $354M $695M $845M $972M $966M $633M
Preferred stock $0.0M โ€” โ€” $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity $1.6M $83.8M $49.2M $38.3M โˆ’$19.3M โˆ’$107M โˆ’$295M โˆ’$456M โˆ’$476M โˆ’$119M
Margins
Gross margin 91.3% 95.5% โ€” 92.4% 91.3% 95.4% 97.6% 98.6% 97.3% 97.8%
Operating margin โˆ’184.4% โˆ’227.9% โˆ’456.2% โˆ’203.7% โˆ’981.1% โˆ’113.1% โˆ’54.8% โˆ’31.3% โˆ’0.6% 39.0%
EBITDA margin โˆ’182.6% โˆ’225.2% โˆ’452.5% โˆ’202.2% โˆ’976.9% โˆ’112.6% โˆ’54.3% โˆ’30.8% โˆ’0.3% 39.1%
Net margin โˆ’209.3% โˆ’261.2% โˆ’490.3% โˆ’223.0% โˆ’1,026.4% โˆ’117.1% โˆ’91.2% โˆ’68.4% โˆ’19.7% 30.2%
FCF margin โˆ’222.8% โˆ’164.7% โˆ’450.0% โˆ’184.1% โˆ’761.4% โˆ’92.0% โˆ’60.3% โˆ’29.4% โˆ’11.8% 39.4%
Returns
Return on capital employed โˆ’137.0% โˆ’55.5% โˆ’121.8% โˆ’119.9% โˆ’76.3% โˆ’36.7% โˆ’33.4% โˆ’28.3% โˆ’0.8% 107.2%
Return on equity โˆ’3,494.6% โˆ’154.2% โˆ’152.3% โˆ’248.9% โˆ’1,925.4% โ€” โ€” โ€” โ€” โ€”
Return on assets โˆ’61.4% โˆ’49.1% โˆ’62.3% โˆ’67.6% โˆ’71.7% โˆ’39.9% โˆ’43.4% โˆ’42.5% โˆ’17.6% 52.5%
Return on tangible equity โˆ’3,494.6% โˆ’78.5% โˆ’205.7% โˆ’284.7% โ€” โ€” โ€” โ€” โ€” โ€”
Growth
Revenue growth โ€” โˆ’4.4% โˆ’18.0% 136.5% โˆ’63.5% 782.4% 72.3% 22.4% 36.0% 94.1%
Share count change โ€” 14.6% 22.2% 12.0% 44.7% 7.1% 3.8% 3.4% 7.5% 5.8%
Financial health
Net debt / EBITDA โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โˆ’0.8x
Debt / equity 14.6x 0.3x 0.6x 1.3x โ€” โ€” โ€” โ€” โ€” โ€”
Interest coverage โˆ’7.5x โˆ’6.7x โˆ’10.3x โˆ’8.4x โˆ’12.1x โˆ’3.0x โˆ’1.5x โˆ’1.0x โˆ’0.0x 4.3x
Current ratio 1.2x 1.7x 1.6x 1.8x 3.1x 5.5x 4.9x 3.3x 2.6x 2.1x
Quick ratio 1.2x 1.7x 1.6x 1.8x 3.0x 5.3x 4.6x 3.1x 2.6x 2.0x
Capital allocation
Capex / revenue 20.0% 1.3% 1.8% 0.7% 2.9% 1.5% 0.5% 0.7% 0.2% 0.3%
Stock comp / revenue 32.2% 50.1% 45.5% 36.3% 83.1% 22.0% 16.5% 16.8% 14.5% 9.7%
Quality scores
Piotroski F-score โ€” 5.0 1.0 4.0 3.0 5.0 4.0 4.0 3.0 7.0
Altman Z'' โˆ’23.2 โˆ’10.9 โˆ’18.0 โˆ’16.5 โˆ’9.3 โˆ’3.7 โˆ’5.9 โˆ’8.1 โˆ’8.8 โˆ’2.6
Accruals ratio โˆ’1.9% โˆ’18.4% โˆ’5.3% โˆ’12.0% โˆ’18.7% โˆ’9.1% โˆ’15.0% โˆ’24.6% โˆ’7.3% โˆ’16.6%

Source: SEC EDGAR XBRL filings (CIK 0000882796). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open